share_log

Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $15 Price Target

Benzinga ·  Aug 14, 2023 08:17

Wedbush analyst Andreas Argyrides reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment